What is NextPoint Therapeutics?
NextPoint Therapeutics is a biotechnology firm dedicated to transforming the landscape of immuno-oncology through its focus on the novel HHLA2 axis, also known as B7-H7. By integrating foundational science with a rigorous clinical biomarker strategy, the company aims to deliver a new class of monotherapies specifically designed for patients who do not respond to existing PD-1/L1 inhibitors. The company's innovative approach utilizes the unique upregulation of HHLA2 in cancer as a critical anchor for tumor-targeting therapeutic modalities, effectively bridging the gap between discovery and clinical application.
How much funding has NextPoint Therapeutics raised?
NextPoint Therapeutics has raised a total of $156.2M across 2 funding rounds:
Series B
$80M
Series B
$42.5M
Series B (2023): $80M with participation from Bayer, Catalio Capital Management, Sanofi Ventures, Sixty Degree Capital, and Invus
Series B (2024): $42.5M led by Arkin Holdings and Catalio Capital Management
Key Investors in NextPoint Therapeutics
Catalio Capital Management
A New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets, with a focus on breakthrough biomedical technology.
Arkin Holdings
A prominent multi-asset manager that oversees significant assets across various sectors, including health and technology, with a specialized arm for healthcare innovations.
Sanofi Ventures
The corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with transformative products of strategic interest to the parent organization.
What's next for NextPoint Therapeutics?
With the recent capital infusion, NextPoint Therapeutics is poised to advance its clinical pipeline and solidify its position in the precision oncology market. The strategic focus will likely center on accelerating the development of its HHLA2-targeted therapies, moving from preclinical validation toward human clinical trials. By maintaining a focus on high-unmet-need patient populations, the company is well-positioned to disrupt the current standard of care. Future milestones will likely involve the expansion of its drug development team and the potential for strategic partnerships to further validate its unique therapeutic modalities in the global oncology market.
See full NextPoint Therapeutics company page
